[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fC4tNdiMmcDYI4ztiyUuNPYk3vFPF3q3mZCP9YU2wIV8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":33,"phaseBuckets":39,"rows":46},"Merz Pharmaceuticals GmbH",[4],61,false,1,28,11405,5,[13,16,19,22,24,26,28,30],{"name":14,"count":15},"Healthy",7,{"name":17,"count":18},"Subjective Tinnitus",4,{"name":20,"count":21},"Glabellar Frown Lines",3,{"name":23,"count":21},"Alzheimer's Disease",{"name":25,"count":21},"Cervical Dystonia",{"name":27,"count":21},"Blepharospasm",{"name":29,"count":21},"Cerebral Palsy",{"name":31,"count":32},"Healthy Subjects",2,[34],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT03992404","Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury","2025-06-19","NT 201",[40,41,42,43,44,45],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[47,138,186,211,235,259,460,533,555,573,599,617,643,661,679,697,773,802,828,846,871,901,919,945],{"intervention":38,"totalTrials":15,"cells":48},{"EARLY_PHASE1":49,"PHASE1":52,"PHASE2":54,"PHASE3":78,"PHASE4":124,"NA":136},{"trials":50,"activeCount":51},[],0,{"trials":53,"activeCount":51},[],{"trials":55,"activeCount":51},[56,66],{"nctId":57,"briefTitle":58,"status":59,"phases":60,"primaryCompletion":61,"completion":61,"start":62,"enrollment":63,"conditions":64,"interventions":65},"NCT00507637","Blepharospasm Short Interval","TERMINATED",[42],"2008-02","2007-08",8,[27],[38],{"nctId":67,"briefTitle":68,"status":69,"phases":70,"primaryCompletion":71,"completion":72,"start":73,"enrollment":74,"conditions":75,"interventions":77},"NCT04766723","A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm","COMPLETED",[42],"2023-04-26","2023-11-21","2021-02-24",78,[76],"Essential Tremor of the Upper Limb",[38],{"trials":79,"activeCount":8,"soonestReadout":37},[80,89,100,109],{"nctId":35,"briefTitle":36,"status":81,"phases":82,"primaryCompletion":37,"completion":83,"start":84,"enrollment":85,"conditions":86,"interventions":88},"ACTIVE_NOT_RECRUITING",[43],"2027-04","2019-09-16",603,[87],"Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury",[38],{"nctId":90,"briefTitle":91,"status":69,"phases":92,"primaryCompletion":93,"completion":94,"start":95,"enrollment":96,"conditions":97,"interventions":98},"NCT00777803","NT 201 (Xeomin®\u002FBocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines",[43],"2009-04","2009-05","2008-11",381,[20],[38,99],"OnabotulinumtoxinA",{"nctId":101,"briefTitle":102,"status":69,"phases":103,"primaryCompletion":104,"completion":104,"start":105,"enrollment":106,"conditions":107,"interventions":108},"NCT00694148","Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines",[43],"2009-01","2008-05",108,[14],[38],{"nctId":110,"briefTitle":111,"status":69,"phases":112,"primaryCompletion":113,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":122},"NCT02270736","Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and\u002For Intellectual Disability",[43],"2018-02-23","2019-05-07","2015-02-09",256,[118,29,119,120,121],"Chronic Troublesome Sialorrhea","Stroke","Traumatic Brain Injury","Intellectual Disability",[123,38],"NT 201 Placebo",{"trials":125,"activeCount":51},[126],{"nctId":127,"briefTitle":128,"status":69,"phases":129,"primaryCompletion":130,"completion":131,"start":132,"enrollment":133,"conditions":134,"interventions":135},"NCT00541905","Daily Dystonia Practice - A Trial to Investigate NT 201, the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Cervical Dystonia",[44],"2008-10","2010-05","2007-09",82,[25],[38],{"trials":137,"activeCount":51},[],{"intervention":139,"totalTrials":21,"cells":140},"Memantine",{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":161,"PHASE4":173,"NA":184},{"trials":142,"activeCount":51},[],{"trials":144,"activeCount":51},[],{"trials":146,"activeCount":51},[147],{"nctId":148,"briefTitle":149,"status":69,"phases":150,"primaryCompletion":151,"completion":152,"start":153,"enrollment":154,"conditions":155,"interventions":160},"NCT01261741","Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems",[42],"2011-08","2011-09","2010-11",299,[156,157,158,159],"Memory Disorder","Retention Disorder, Cognitive","Subjective Cognitive Impairment","Memory, Concentration or Attention Problems",[139],{"trials":162,"activeCount":51},[163],{"nctId":164,"briefTitle":165,"status":69,"phases":166,"primaryCompletion":167,"completion":167,"start":168,"enrollment":169,"conditions":170,"interventions":171},"NCT00804271","Memantine and Validation of a New Alzheimer's Disease Scale",[43],"2009-11","2008-12",487,[23],[172],"memantine",{"trials":174,"activeCount":51},[175],{"nctId":176,"briefTitle":177,"status":59,"phases":178,"primaryCompletion":94,"completion":179,"start":180,"enrollment":181,"conditions":182,"interventions":183},"NCT00649220","Memantine and Antipsychotics Use",[44],"2009-06","2008-07",19,[23],[139],{"trials":185,"activeCount":51},[],{"intervention":187,"totalTrials":8,"cells":188},"Hyaluronic acid filler\u002FIMD1 basic",{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":193,"PHASE3":195,"PHASE4":197,"NA":209},{"trials":190,"activeCount":51},[],{"trials":192,"activeCount":51},[],{"trials":194,"activeCount":51},[],{"trials":196,"activeCount":51},[],{"trials":198,"activeCount":51},[199],{"nctId":200,"briefTitle":201,"status":69,"phases":202,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":208},"NCT00429520","Hyaluronic Acid Filler IMD1 Basic for Correction of Nasolabial Folds",[44],"2006-12","2005-12",114,[207],"Nasolabial Folds",[187],{"trials":210,"activeCount":51},[],{"intervention":212,"totalTrials":8,"cells":213},"Contractubex",{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":220,"PHASE4":222,"NA":233},{"trials":215,"activeCount":51},[],{"trials":217,"activeCount":51},[],{"trials":219,"activeCount":51},[],{"trials":221,"activeCount":51},[],{"trials":223,"activeCount":51},[224],{"nctId":225,"briefTitle":226,"status":69,"phases":227,"primaryCompletion":228,"completion":228,"start":229,"enrollment":6,"conditions":230,"interventions":232},"NCT01112371","Contractubex Treatment in Scars After Abdominal Caesarean Section",[44],"2012-02","2011-02",[231],"Scars",[212],{"trials":234,"activeCount":51},[],{"intervention":236,"totalTrials":8,"cells":237},"Xeomin®",{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":242,"PHASE3":244,"PHASE4":246,"NA":257},{"trials":239,"activeCount":51},[],{"trials":241,"activeCount":51},[],{"trials":243,"activeCount":51},[],{"trials":245,"activeCount":51},[],{"trials":247,"activeCount":51},[248],{"nctId":249,"briefTitle":250,"status":69,"phases":251,"primaryCompletion":252,"completion":252,"start":253,"enrollment":254,"conditions":255,"interventions":256},"NCT01486264","Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex",[44],"2016-03-29","2012-01-20",283,[25],[236],{"trials":258,"activeCount":51},[],{"intervention":260,"totalTrials":181,"cells":261},"IncobotulinumtoxinA",{"EARLY_PHASE1":262,"PHASE1":264,"PHASE2":277,"PHASE3":300,"PHASE4":456,"NA":458},{"trials":263,"activeCount":51},[],{"trials":265,"activeCount":51},[266],{"nctId":267,"briefTitle":268,"status":69,"phases":269,"primaryCompletion":270,"completion":271,"start":272,"enrollment":273,"conditions":274,"interventions":276},"NCT05585398","A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods",[41],"2023-02-24","2023-04-13","2022-10-19",40,[275],"N\u002FA, as no Specific Medical Condition Will be Treated",[260],{"trials":278,"activeCount":51},[279,289],{"nctId":280,"briefTitle":281,"status":59,"phases":282,"primaryCompletion":283,"completion":284,"start":285,"enrollment":63,"conditions":286,"interventions":288},"NCT01515371","Dose Finding Study for a Botulinum Toxin Type A Injection to Treat Habitual Snoring",[42],"2012-09","2012-11","2012-01",[287],"Habitual Snoring",[260],{"nctId":290,"briefTitle":291,"status":69,"phases":292,"primaryCompletion":293,"completion":294,"start":295,"enrollment":296,"conditions":297,"interventions":299},"NCT02207946","Botulinum Toxin A to Treat Arm Tremor",[42],"2016-05-09","2016-09-26","2014-12-05",30,[298],"Essential Tremor of the Upper Limbs",[260],{"trials":301,"activeCount":51},[302,311,321,329,339,348,358,369,379,386,397,405,417,427,437,447],{"nctId":303,"briefTitle":304,"status":69,"phases":305,"primaryCompletion":306,"completion":307,"start":308,"enrollment":116,"conditions":309,"interventions":310},"NCT00430963","IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines",[43],"2007-04","2007-11","2006-10",[20],[260],{"nctId":312,"briefTitle":313,"status":69,"phases":314,"primaryCompletion":315,"completion":105,"start":316,"enrollment":317,"conditions":318,"interventions":320},"NCT00432666","IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb",[43],"2006-11","2006-06",148,[319],"Post-stroke Upper Limb Spasticity",[260],{"nctId":322,"briefTitle":304,"status":69,"phases":323,"primaryCompletion":324,"completion":179,"start":130,"enrollment":325,"conditions":326,"interventions":328},"NCT00770211",[43],"2009-03",271,[327],"Moderate to Severe Glabellar Frown Lines",[260],{"nctId":330,"briefTitle":331,"status":69,"phases":332,"primaryCompletion":333,"completion":179,"start":334,"enrollment":335,"conditions":336,"interventions":337},"NCT00407030","IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia",[43],"2008-01","2006-07",233,[25],[338,338],"incobotulinumtoxinA",{"nctId":340,"briefTitle":341,"status":69,"phases":342,"primaryCompletion":343,"completion":344,"start":308,"enrollment":345,"conditions":346,"interventions":347},"NCT00406367","IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm",[43],"2008-04","2009-07",109,[27],[338],{"nctId":349,"briefTitle":350,"status":69,"phases":351,"primaryCompletion":352,"completion":352,"start":353,"enrollment":354,"conditions":355,"interventions":357},"NCT01905683","Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy",[43],"2017-01","2013-08",370,[356],"Lower Limb and Combined Lower Limb and Upper Limb Spasticity Due to Cerebral Palsy",[260],{"nctId":359,"briefTitle":360,"status":69,"phases":361,"primaryCompletion":362,"completion":363,"start":364,"enrollment":365,"conditions":366,"interventions":368},"NCT01464307","Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke",[43],"2014-08","2015-05","2011-12",290,[367],"Post-stroke Spasticity of the Lower Limb",[260],{"nctId":370,"briefTitle":371,"status":69,"phases":372,"primaryCompletion":373,"completion":373,"start":374,"enrollment":375,"conditions":376,"interventions":378},"NCT01603459","Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm",[43],"2014-09","2012-05",155,[377],"Spasticity of the Upper and Lower Limb Due to Cerebral Causes",[260],{"nctId":380,"briefTitle":381,"status":69,"phases":382,"primaryCompletion":324,"completion":179,"start":130,"enrollment":383,"conditions":384,"interventions":385},"NCT00770029","IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2",[43],276,[327],[260],{"nctId":387,"briefTitle":388,"status":69,"phases":389,"primaryCompletion":390,"completion":391,"start":392,"enrollment":393,"conditions":394,"interventions":396},"NCT02002884","Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy",[43],"2017-07-04","2018-08-28","2014-03-28",351,[29,395],"Spasticity",[260,260,260],{"nctId":398,"briefTitle":399,"status":69,"phases":400,"primaryCompletion":61,"completion":105,"start":132,"enrollment":401,"conditions":402,"interventions":404},"NCT00541723","Efficacy and Safety of NT 201 in the Treatment of Lateral Periorbital Wrinkles",[43],111,[403],"Lateral Periorbital Wrinkles",[260],{"nctId":406,"briefTitle":407,"status":69,"phases":408,"primaryCompletion":409,"completion":410,"start":411,"enrollment":412,"conditions":413,"interventions":416},"NCT02091739","Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions",[43],"2015-08","2016-11","2014-04",184,[118,414,415,120],"Parkinson's Disease","Post-stroke",[260,260],{"nctId":418,"briefTitle":419,"status":69,"phases":420,"primaryCompletion":421,"completion":422,"start":152,"enrollment":423,"conditions":424,"interventions":426},"NCT01392300","Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke",[43],"2013-03","2014-02",317,[425],"Post-stroke Spasticity of the Upper Limb",[260],{"nctId":428,"briefTitle":429,"status":69,"phases":430,"primaryCompletion":431,"completion":431,"start":432,"enrollment":433,"conditions":434,"interventions":436},"NCT00512135","Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines",[43],"2009-12-28","2007-06-18",801,[435],"Glabellar Lines",[260],{"nctId":438,"briefTitle":439,"status":69,"phases":440,"primaryCompletion":409,"completion":441,"start":442,"enrollment":443,"conditions":444,"interventions":446},"NCT01893411","Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy",[43],"2016-05","2013-06",311,[445],"Lower Limb Spasticity Due to Cerebral Palsy",[260,260,260],{"nctId":448,"briefTitle":449,"status":69,"phases":450,"primaryCompletion":333,"completion":105,"start":451,"enrollment":452,"conditions":453,"interventions":455},"NCT00465738","IncobotulinumtoxinA (Xeomin) for Upper Limb Spasticity",[43],"2007-02",216,[454],"Upper Limb Spasticity",[338],{"trials":457,"activeCount":51},[],{"trials":459,"activeCount":51},[],{"intervention":461,"totalTrials":15,"cells":462},"Neramexane mesylate",{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":474,"PHASE3":493,"PHASE4":529,"NA":531},{"trials":464,"activeCount":51},[],{"trials":466,"activeCount":51},[467],{"nctId":468,"briefTitle":469,"status":69,"phases":470,"primaryCompletion":324,"completion":179,"start":180,"enrollment":471,"conditions":472,"interventions":473},"NCT00712283","Investigate the Effect of Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers",[41],64,[14],[461],{"trials":475,"activeCount":51},[476,485],{"nctId":477,"briefTitle":478,"status":69,"phases":479,"start":105,"enrollment":480,"conditions":481,"interventions":484},"NCT00661440","Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus",[42],48,[482,483],"Nystagmus, Congenital Idiopathic","Nystagmus, Acquired",[461],{"nctId":486,"briefTitle":487,"status":59,"phases":488,"start":94,"enrollment":480,"conditions":489,"interventions":492},"NCT00799942","Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus",[42],[490,483,491],"Nystagmus, Congenital","Multiple Sclerosis",[461],{"trials":494,"activeCount":51},[495,502,512,520],{"nctId":496,"briefTitle":497,"status":59,"phases":498,"primaryCompletion":364,"completion":364,"start":104,"enrollment":499,"conditions":500,"interventions":501},"NCT00827008","Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus",[43],821,[17],[461],{"nctId":503,"briefTitle":504,"status":69,"phases":505,"primaryCompletion":506,"completion":507,"start":508,"enrollment":509,"conditions":510,"interventions":511},"NCT00955799","Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus",[43],"2011-05","2011-06","2009-09",455,[17],[461],{"nctId":513,"briefTitle":514,"status":69,"phases":515,"primaryCompletion":516,"completion":516,"start":95,"enrollment":517,"conditions":518,"interventions":519},"NCT00772980","Efficacy, Safety and Tolerability of Neramexane in Comparison to Placebo in Patients With Subjective Tinnitus",[43],"2010-06",400,[17],[461],{"nctId":521,"briefTitle":522,"status":69,"phases":523,"primaryCompletion":524,"completion":524,"start":525,"enrollment":526,"conditions":527,"interventions":528},"NCT00739635","Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus",[43],"2010-02","2008-09",411,[17],[461],{"trials":530,"activeCount":51},[],{"trials":532,"activeCount":51},[],{"intervention":534,"totalTrials":8,"cells":535},"Memantine-HCl",{"EARLY_PHASE1":536,"PHASE1":538,"PHASE2":540,"PHASE3":542,"PHASE4":551,"NA":553},{"trials":537,"activeCount":51},[],{"trials":539,"activeCount":51},[],{"trials":541,"activeCount":51},[],{"trials":543,"activeCount":51},[544],{"nctId":545,"briefTitle":546,"status":69,"phases":547,"primaryCompletion":168,"completion":168,"start":307,"enrollment":548,"conditions":549,"interventions":550},"NCT00624026","Memantine - Communication Study",[43],107,[23],[534],{"trials":552,"activeCount":51},[],{"trials":554,"activeCount":51},[],{"intervention":99,"totalTrials":8,"cells":556},{"EARLY_PHASE1":557,"PHASE1":559,"PHASE2":561,"PHASE3":563,"PHASE4":569,"NA":571},{"trials":558,"activeCount":51},[],{"trials":560,"activeCount":51},[],{"trials":562,"activeCount":51},[],{"trials":564,"activeCount":51},[565],{"nctId":90,"briefTitle":91,"status":69,"phases":566,"primaryCompletion":93,"completion":94,"start":95,"enrollment":96,"conditions":567,"interventions":568},[43],[20],[38,99],{"trials":570,"activeCount":51},[],{"trials":572,"activeCount":51},[],{"intervention":574,"totalTrials":8,"cells":575},"Akatinol Memantine 20 mg",{"EARLY_PHASE1":576,"PHASE1":578,"PHASE2":580,"PHASE3":582,"PHASE4":595,"NA":597},{"trials":577,"activeCount":51},[],{"trials":579,"activeCount":51},[],{"trials":581,"activeCount":51},[],{"trials":583,"activeCount":51},[584],{"nctId":585,"briefTitle":586,"status":69,"phases":587,"primaryCompletion":588,"completion":588,"start":589,"enrollment":590,"conditions":591,"interventions":593},"NCT03986424","Local Study of Akatinol Memantine in VaD in Russia",[43],"2022-06-01","2018-01-23",130,[592],"Vascular Dementia",[574,594],"Akatinol Memantine 10 mg",{"trials":596,"activeCount":51},[],{"trials":598,"activeCount":51},[],{"intervention":594,"totalTrials":8,"cells":600},{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":607,"PHASE4":613,"NA":615},{"trials":602,"activeCount":51},[],{"trials":604,"activeCount":51},[],{"trials":606,"activeCount":51},[],{"trials":608,"activeCount":51},[609],{"nctId":585,"briefTitle":586,"status":69,"phases":610,"primaryCompletion":588,"completion":588,"start":589,"enrollment":590,"conditions":611,"interventions":612},[43],[592],[574,594],{"trials":614,"activeCount":51},[],{"trials":616,"activeCount":51},[],{"intervention":618,"totalTrials":8,"cells":619},"IncobulinumtoxinA (Xeomin), 25 Units",{"EARLY_PHASE1":620,"PHASE1":622,"PHASE2":624,"PHASE3":626,"PHASE4":639,"NA":641},{"trials":621,"activeCount":51},[],{"trials":623,"activeCount":51},[],{"trials":625,"activeCount":51},[],{"trials":627,"activeCount":51},[628],{"nctId":629,"briefTitle":630,"status":69,"phases":631,"primaryCompletion":632,"completion":410,"start":633,"enrollment":6,"conditions":634,"interventions":636},"NCT01896895","Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid",[43],"2016-04","2013-11",[635],"Bilateral Blepharospasm (BEB)",[618,637,638],"IncobotulinumtoxinA (Xeomin), 12.5 Units","IncobotulinumtoxinA (Xeomin), 35 Units",{"trials":640,"activeCount":51},[],{"trials":642,"activeCount":51},[],{"intervention":637,"totalTrials":8,"cells":644},{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":651,"PHASE4":657,"NA":659},{"trials":646,"activeCount":51},[],{"trials":648,"activeCount":51},[],{"trials":650,"activeCount":51},[],{"trials":652,"activeCount":51},[653],{"nctId":629,"briefTitle":630,"status":69,"phases":654,"primaryCompletion":632,"completion":410,"start":633,"enrollment":6,"conditions":655,"interventions":656},[43],[635],[618,637,638],{"trials":658,"activeCount":51},[],{"trials":660,"activeCount":51},[],{"intervention":638,"totalTrials":8,"cells":662},{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":669,"PHASE4":675,"NA":677},{"trials":664,"activeCount":51},[],{"trials":666,"activeCount":51},[],{"trials":668,"activeCount":51},[],{"trials":670,"activeCount":51},[671],{"nctId":629,"briefTitle":630,"status":69,"phases":672,"primaryCompletion":632,"completion":410,"start":633,"enrollment":6,"conditions":673,"interventions":674},[43],[635],[618,637,638],{"trials":676,"activeCount":51},[],{"trials":678,"activeCount":51},[],{"intervention":123,"totalTrials":8,"cells":680},{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":685,"PHASE3":687,"PHASE4":693,"NA":695},{"trials":682,"activeCount":51},[],{"trials":684,"activeCount":51},[],{"trials":686,"activeCount":51},[],{"trials":688,"activeCount":51},[689],{"nctId":110,"briefTitle":111,"status":69,"phases":690,"primaryCompletion":113,"completion":114,"start":115,"enrollment":116,"conditions":691,"interventions":692},[43],[118,29,119,120,121],[123,38],{"trials":694,"activeCount":51},[],{"trials":696,"activeCount":51},[],{"intervention":698,"totalTrials":63,"cells":699},"Neramexane",{"EARLY_PHASE1":700,"PHASE1":702,"PHASE2":755,"PHASE3":767,"PHASE4":769,"NA":771},{"trials":701,"activeCount":51},[],{"trials":703,"activeCount":51},[704,711,718,726,734,741,748],{"nctId":705,"briefTitle":706,"status":69,"phases":707,"primaryCompletion":708,"completion":708,"start":344,"conditions":709,"interventions":710},"NCT00936026","Open, Single Center, Three Periods, Fixed Sequence Design Study on the Effects of Clopidogrel Co-administration on the Pharmacokinetics of Neramexane",[41],"2009-12",[31],[698],{"nctId":712,"briefTitle":713,"status":69,"phases":714,"primaryCompletion":708,"completion":708,"start":715,"conditions":716,"interventions":717},"NCT00972127","Changes in the Renal Excretion of Neramexane by Acidification of Urinary pH Study With and Without Application of a Urinary pH Acidification Regimen",[41],"2009-10",[14],[698],{"nctId":719,"briefTitle":720,"status":69,"phases":721,"primaryCompletion":722,"completion":722,"start":508,"enrollment":723,"conditions":724,"interventions":725},"NCT00983099","Evaluation of Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Neramexane Mesylate in Healthy Japanese Subjects",[41],"2010-09",56,[14],[698],{"nctId":727,"briefTitle":728,"status":69,"phases":729,"primaryCompletion":516,"completion":516,"start":730,"enrollment":63,"conditions":731,"interventions":733},"NCT01109680","A Single Center, Open-Label Study to Quantify Metabolites of [14C]-Neramexane in Plasma and Urine in Healthy Male Subjects",[41],"2010-04",[732],"Metabolism of Neramexane",[698],{"nctId":735,"briefTitle":736,"status":69,"phases":737,"primaryCompletion":708,"completion":708,"start":738,"conditions":739,"interventions":740},"NCT00955760","Study Analyzing the Effect of Rifampicin Administration on the Pharmacokinetics of Neramexane Mesylate",[41],"2009-08",[14],[698],{"nctId":742,"briefTitle":743,"status":69,"phases":744,"primaryCompletion":167,"completion":167,"start":179,"enrollment":745,"conditions":746,"interventions":747},"NCT00915174","Study to Evaluate the Effects of Neramexane on the Pharmacokinetics of a Combined Drospirenone\u002FEthinyl Estradiol Oral Contraceptive in Healthy Female Subjects",[41],36,[14],[698],{"nctId":749,"briefTitle":750,"status":69,"phases":751,"primaryCompletion":730,"completion":730,"start":508,"enrollment":752,"conditions":753,"interventions":754},"NCT00978614","Evaluation of Dose-Dependent Repeated-Dose Neramexane Effects on Cardiac Repolarisation (QT\u002FQTc Interval Duration): Electrocardiogram (ECG) Study in Healthy Adult Subjects",[41],126,[31],[698],{"trials":756,"activeCount":51},[757],{"nctId":758,"briefTitle":759,"status":69,"phases":760,"primaryCompletion":761,"completion":761,"start":762,"enrollment":763,"conditions":764,"interventions":766},"NCT00405886","Neramexane for Tinnitus",[42],"2007-03","2005-10",431,[765],"Tinnitus",[698],{"trials":768,"activeCount":51},[],{"trials":770,"activeCount":51},[],{"trials":772,"activeCount":51},[],{"intervention":774,"totalTrials":32,"cells":775},"Botulinum neurotoxin type A, free of complexing proteins",{"EARLY_PHASE1":776,"PHASE1":778,"PHASE2":787,"PHASE3":796,"PHASE4":798,"NA":800},{"trials":777,"activeCount":51},[],{"trials":779,"activeCount":51},[780],{"nctId":781,"briefTitle":782,"status":69,"phases":783,"primaryCompletion":61,"completion":784,"start":62,"enrollment":296,"conditions":785,"interventions":786},"NCT00515944","Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products",[41],"2008-06",[14],[774],{"trials":788,"activeCount":51},[789],{"nctId":790,"briefTitle":791,"status":69,"phases":792,"completion":62,"start":315,"enrollment":793,"conditions":794,"interventions":795},"NCT00430586","Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines",[42],191,[20],[774],{"trials":797,"activeCount":51},[],{"trials":799,"activeCount":51},[],{"trials":801,"activeCount":51},[],{"intervention":803,"totalTrials":8,"cells":804},"Xeomin",{"EARLY_PHASE1":805,"PHASE1":807,"PHASE2":809,"PHASE3":822,"PHASE4":824,"NA":826},{"trials":806,"activeCount":51},[],{"trials":808,"activeCount":51},[],{"trials":810,"activeCount":51},[811],{"nctId":812,"briefTitle":813,"status":69,"phases":814,"primaryCompletion":815,"completion":815,"start":816,"enrollment":471,"conditions":817,"interventions":820},"NCT02188277","Treatment With Xeomin Versus Botox in Children With Spastic Equine and Equinovarus Foot Deformation in Pediatric Cerebral Palsy",[42],"2016-12","2014-07",[29,818,819],"Spastic Paraplegia and Hemiparesis","Equine and Equinovarus Foot Deformation",[803,821],"Botox®",{"trials":823,"activeCount":51},[],{"trials":825,"activeCount":51},[],{"trials":827,"activeCount":51},[],{"intervention":821,"totalTrials":8,"cells":829},{"EARLY_PHASE1":830,"PHASE1":832,"PHASE2":834,"PHASE3":840,"PHASE4":842,"NA":844},{"trials":831,"activeCount":51},[],{"trials":833,"activeCount":51},[],{"trials":835,"activeCount":51},[836],{"nctId":812,"briefTitle":813,"status":69,"phases":837,"primaryCompletion":815,"completion":815,"start":816,"enrollment":471,"conditions":838,"interventions":839},[42],[29,818,819],[803,821],{"trials":841,"activeCount":51},[],{"trials":843,"activeCount":51},[],{"trials":845,"activeCount":51},[],{"intervention":847,"totalTrials":8,"cells":848},"NT 201, a Botulinum neurotoxin type A, free of complexing proteins",{"EARLY_PHASE1":849,"PHASE1":851,"PHASE2":853,"PHASE3":865,"PHASE4":867,"NA":869},{"trials":850,"activeCount":51},[],{"trials":852,"activeCount":51},[],{"trials":854,"activeCount":51},[855],{"nctId":856,"briefTitle":857,"status":858,"phases":859,"primaryCompletion":860,"completion":860,"start":861,"enrollment":51,"conditions":862,"interventions":864},"NCT00773591","Effect of NT 201 (Botulinum Neurotoxin Type A Free of Complexing Proteins) on Sleep-related Breathing Disorders","WITHDRAWN",[42],"2010-10","2010-03",[863],"Sleep-Disordered Breathing",[847],{"trials":866,"activeCount":51},[],{"trials":868,"activeCount":51},[],{"trials":870,"activeCount":51},[],{"intervention":872,"totalTrials":8,"cells":873},"Pantovigar",{"EARLY_PHASE1":874,"PHASE1":876,"PHASE2":878,"PHASE3":895,"PHASE4":897,"NA":899},{"trials":875,"activeCount":51},[],{"trials":877,"activeCount":51},[],{"trials":879,"activeCount":51},[880],{"nctId":881,"briefTitle":882,"status":69,"phases":883,"primaryCompletion":884,"completion":885,"start":886,"enrollment":887,"conditions":888,"interventions":893},"NCT01900041","A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss",[42],"2013-05","2013-07","2012-04",74,[889,890,891,892],"Female Pattern Hair Loss","Androgenetic Alopecia (AGA)","Ludwig Type 1","Ludwig Type 2",[872,894],"Minoxidil 2% only",{"trials":896,"activeCount":51},[],{"trials":898,"activeCount":51},[],{"trials":900,"activeCount":51},[],{"intervention":894,"totalTrials":8,"cells":902},{"EARLY_PHASE1":903,"PHASE1":905,"PHASE2":907,"PHASE3":913,"PHASE4":915,"NA":917},{"trials":904,"activeCount":51},[],{"trials":906,"activeCount":51},[],{"trials":908,"activeCount":51},[909],{"nctId":881,"briefTitle":882,"status":69,"phases":910,"primaryCompletion":884,"completion":885,"start":886,"enrollment":887,"conditions":911,"interventions":912},[42],[889,890,891,892],[872,894],{"trials":914,"activeCount":51},[],{"trials":916,"activeCount":51},[],{"trials":918,"activeCount":51},[],{"intervention":920,"totalTrials":8,"cells":921},"MRZ-99030 eye drops 5mg\u002FmL",{"EARLY_PHASE1":922,"PHASE1":924,"PHASE2":937,"PHASE3":939,"PHASE4":941,"NA":943},{"trials":923,"activeCount":51},[],{"trials":925,"activeCount":51},[926],{"nctId":927,"briefTitle":928,"status":69,"phases":929,"primaryCompletion":930,"completion":930,"start":931,"enrollment":932,"conditions":933,"interventions":935},"NCT01714960","Safety and Tolerability of MRZ-99030 Eye Drops in Healthy Volunteers and Glaucoma Patients",[41],"2013-12","2012-10",70,[934],"Healthy Volunteers and Glaucoma Patients",[920,936],"MRZ-99030 eye drops 20mg\u002FmL",{"trials":938,"activeCount":51},[],{"trials":940,"activeCount":51},[],{"trials":942,"activeCount":51},[],{"trials":944,"activeCount":51},[],{"intervention":936,"totalTrials":8,"cells":946},{"EARLY_PHASE1":947,"PHASE1":949,"PHASE2":955,"PHASE3":957,"PHASE4":959,"NA":961},{"trials":948,"activeCount":51},[],{"trials":950,"activeCount":51},[951],{"nctId":927,"briefTitle":928,"status":69,"phases":952,"primaryCompletion":930,"completion":930,"start":931,"enrollment":932,"conditions":953,"interventions":954},[41],[934],[920,936],{"trials":956,"activeCount":51},[],{"trials":958,"activeCount":51},[],{"trials":960,"activeCount":51},[],{"trials":962,"activeCount":51},[]]